Figure 2
From: Targeting melanoma with front-line therapy does not abrogate Nodal-expressing tumor cells
Anchorage-independent colony formation (clonogenic) potential of melanoma cells is most inhibited by combination treatment with BRAFi plus anti-Nodal mAb. Changes in the anchorage-independent growth (clonogenicity) of A375SM-L1 cells in response to treatment with an anti-Nodal mAb (WS65), dabrafenib or a combination of both 3 weeks after treatment are evaluated. (a) Representative images of the A375SM-L1 cell clusters formed in soft agar 3 weeks after removal from treatment with WS65 mAb, dabrafenib or a combination compared with no treatment (control) or treatment with IgG (IgG control) or DMSO alone (DMSO control). (b) Relative colony formation of A375SM-L1 cells cultured on soft agar (≥50 cells per cluster, shown in a) following 72-h treatment with 1 μg/ml WS65 mAb, 1 nM dabrafenib, or a combination of both 1 nM dabrafenib and 1 μg/ml of WS65 mAb compared with untreated control cells were determined as a percentage (mean±s.e.m.) of untreated control cells (*P≤0.05). The significance in colony formation between either the 1 μg/ml WS65 mAb or 1 nM dabrafenib treatments and the combination of both is also significantly different (**P≤0.05).
